Cohance Lifesciences Ratios

Cohance Lifesciences Ltd Ratios

The Cohance Lifesciences Ltd Ratios page provides a complete fundamental analysis of Cohance Lifesciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Cohance Lifesciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Cohance Lifesciences Ltd (NSE: COHANCE, BSE: 543064) is currently trading at ₹311.95, with a market capitalization of ₹115.5B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Cohance Lifesciences Ltd remains a key stock for fundamental analysis using Cohance Lifesciences Ltd Ratios.

Cohance Lifesciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Cohance Lifesciences Ltd P/E ratio currently stands at 110.76, making it one of the most tracked metrics in Cohance Lifesciences Ltd Ratios.

Historically, the Cohance Lifesciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 110.76
• 2023: 57.36
• 2022: 29.26
• 2021: 34.66
• 2020: 34.80

The rising Cohance Lifesciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Cohance Lifesciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 17.40.

Historical P/B trend:

• 2024: 17.40
• 2023: 8.40
• 2022: 6.93
• 2021: 10.30

Cohance Lifesciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Cohance Lifesciences Ltd P/S ratio currently stands at 25.14, an important part of Cohance Lifesciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 25.14
• 2023: 16.63
• 2022: 9.04
• 2021: 12.04

The rising Cohance Lifesciences Ltd P/S ratio indicates improved revenue valuation by investors.

Cohance Lifesciences Ltd Price to Cash Flow Ratio (P/CF)

The Cohance Lifesciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 104.19.

Historical Cohance Lifesciences Ltd Price to Cash Flow Ratio:

• 2024: 104.19
• 2023: 45.21
• 2022: 26.66
• 2021: 48.58
• 2020: 33.73

The rising Cohance Lifesciences Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Cohance Lifesciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Cohance Lifesciences Ltd EV currently stands at ₹298.04B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 298.04B
• 2023: 164.64B
• 2022: 116.17B
• 2021: 152.99B

Cohance Lifesciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Cohance Lifesciences Ltd EV/EBITDA ratio is currently 74.62, a key metric in Cohance Lifesciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 74.62
• 2023: 40.67
• 2022: 19.90
• 2021: 26.19

Higher Cohance Lifesciences Ltd EV/EBITDA suggests premium valuation.

Cohance Lifesciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Cohance Lifesciences Ltd D/E ratio is currently 0.16, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.16
• 2023: 0.03
• 2022: 0.04
• 2021: 0.06

Cohance Lifesciences Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Cohance Lifesciences Ltd ROE currently stands at 14.30%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 14.30
• 2023: 15.86
• 2022: 25.21
• 2021: 33.52

Cohance Lifesciences Ltd maintains stable profitability levels.

Cohance Lifesciences Ltd Ratios Analysis Summary

The Cohance Lifesciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Cohance Lifesciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Cohance Lifesciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.